H.B. Fuller (FUL) Q2 2026 earnings review
Strong Operational Execution Overshadowed by Transformational M&A Leverage
H.B. Fuller delivered an objectively strong Q2, posting 19% adjusted EPS growth and expanding adjusted gross margins by 200 bps to 34.2%. The company successfully flexed its pricing power (+3.0%) to offset raw material inflation and navigated extreme supply chain disruptions, allowing them to raise the midpoint of their FY26 earnings guidance. However, the core operational beat was entirely overshadowed by the announcement of a £715M ($900M+) all-cash offer for Advanced Medical Solutions (AMS). While strategically sound for pivoting into high-margin medical end markets, the deal pushes pro forma net leverage to a highly elevated 4.0x, triggering immediate market skepticism and an ~10% stock sell-off. Management now faces a monumental dual-integration challenge: executing the AMS takeover while simultaneously running their internal 'Quantum Leap' restructuring program.
🐂 Bull Case
The aggressive 10%+ global price hikes announced in Q1 are flowing through perfectly. Pricing contributed 3.0% to revenue growth in Q2, fully insulating margins against raw material shocks.
The AMS acquisition increases medical exposure to 10% of total sales. With $55M in targeted synergies, FUL expects to double AMS's profitability and drive segment margins beyond 30% by 2030.
🐻 Bear Case
Pro forma net leverage jumps to 4.0x. This suspends all other M&A activity and leaves the company highly vulnerable if macroeconomic conditions deteriorate or synergy targets miss.
Despite a sequential recovery, volume remains negative (-0.4%). Management is bracing for mid-single-digit volume declines in H2 due to a tapped-out global consumer.
⚖️ Verdict: ⚪
Hold. The underlying business is humming with excellent margin expansion and pricing discipline. However, spiking leverage to 4.0x at the peak of an interest rate cycle to buy a UK asset introduces significant near-term execution risk.
Key Themes
Leverage Spikes on AMS Acquisition
The £715M AMS deal radically alters H.B. Fuller's capital structure. To fund the all-cash transaction, FUL has secured $1B in new debt, pushing net leverage from a comfortable 3.1x today to 4.0x pro forma at close. Management is pausing all other M&A to focus on aggressive debt paydown, targeting a return to 2.5x-3.0x within two years. This assumes flawless execution on both AMS synergies and baseline cash flow generation.
Swift Pricing Actions Save Margins
Following severe supply chain disruptions and over 40 force majeure notices in Q1, FUL commanded aggressive price increases. This yielded a 3.0% price contribution in Q2, a sharp acceleration from 0.6% in Q1. This pricing power drove adjusted gross margins up 200 bps year-over-year to 34.2%, proving the stickiness and necessity of FUL's specialized formulations.
Building Adhesives (BAS) Reversing to Growth
Reversing its recent trend as a laggard, the BAS segment accelerated to 6.2% organic growth in Q2 (up from -5.1% in Q1). Management cited a robust construction season, strength in glass and infrastructure, and success in niche high-value markets like data centers and LNG facilities. Operating profit for the segment surged 10% YoY.
Consumer Packaging Volumes Remain Stressed
While total company volume improved from -7.2% to -0.4% sequentially, management remains highly cautious. They are guiding for mid-single-digit volume declines in H2, anticipating that inflation will continue to crush consumer spending. This will disproportionately hit the Hygiene, Health and Consumable (HHC) segment as consumers trade down and buy smaller packaging.
Solar Divestiture Masking Engineering Adhesives Strength
On paper, Engineering Adhesives (EA) organic revenue declined 1.0%. However, this includes the intentional run-off of lower-margin solar sealants. Excluding the solar drag, EA grew 5% organically, fueled by >30% growth in aerospace and double-digit growth in electronics and general industries. Automotive remains a notable weak spot globally.
SG&A Expense Inflation
Adjusted SG&A rose 11% year-over-year to $196M. While management notes this is only up ~3% when adjusting for FX and variable compensation tied to higher profits, the nominal dollar increase is eating into the gross margin improvements. Strict cost control will be vital as volume softens in H2.
Other KPIs
A record for the second quarter, up 10% year-over-year, driven primarily by higher net income. This underscores healthy working capital management, which sequentially improved by 260 basis points to 16.4% of annualized revenue.
Decelerating slightly from 22.9% a year ago. Favorable pricing and restructuring savings were offset by higher variable compensation. It remains the company's most profitable segment.
Accelerating significantly from 15.6% a year ago. The segment saw a massive 230 bps improvement driven strictly by successful pricing execution against raw material inflation.
Guidance
Accelerating. The company raised the bottom end of the range (previously $645M - $675M). This represents steady growth and confidence that the 3.0% pricing tailwind achieved in Q2 will persist through the back half of the year.
Accelerating. Raised from the prior outlook of $4.55 - $4.90, reflecting the strong flow-through of Q2's 19% EPS growth and the repurchase of 750,000 shares in the quarter.
Stable. Represents consistent sequential performance compared to the $181M delivered in Q2, even as management braces for tougher volume comps and an uncertain consumer environment.
Stable. Management maintained this guidance range. Hitting this target will be absolutely critical to begin aggressively paying down the new AMS deal debt in 2027.
Key Questions
AMS Integration vs Quantum Leap
You are currently undergoing a massive internal restructuring program with 'Quantum Leap' while simultaneously committing to a $900M+ acquisition. How are you ring-fencing resources to ensure neither integration fails, especially given the aggressive $55M synergy target for AMS?
H2 Volume Conservatism
Volume inflected sharply from -7.2% in Q1 to -0.4% in Q2. Yet, you are maintaining guidance for mid-single-digit volume declines in the back half. Are you actively seeing order books deteriorate in consumer packaging, or is this just extreme macro conservatism?
Pricing Durability
If raw material costs begin to broadly deflate later this year, what contractual or competitive mechanisms do you have in place to ensure you can hold onto the 3.0% pricing gains achieved this quarter?
Path to Deleveraging
With leverage stepping up to 4.0x, is the resumption of your share repurchase program (750K shares in Q2) now completely suspended until you return to the 2.5x-3.0x target?